Table 6 Follow-up of CXCR4 and CCR5 expression in CD3-/CD4+ monocytes
From: In vivo effect of statins on the expression of the HIV co-receptors CCR5 and CXCR4
| Â | Median (Interquartile range) | Comparison by Anova | |||
|---|---|---|---|---|---|
CD3-/CD4+ monocytes | Day 0 | Day 7 | Day 30 | Day 45 | |
% CXCR4+ | Â | Â | |||
Controls without statins (n = 7) | 81.1 (61.0 - 83.5) | 65.7 (41.9 - 85.4) | 89.6 (55.6 - 93.0) | 87.2 (60.7 - 91.2) | NS |
Lovastatin (n = 10) | 48.6 (43.7 - 76.3) | 34.8 (16.1 - 50.2) | 69.7 (51.5 - 81.6) | 57.7 (37.2 - 88.9) | NS |
Atorvastatin (n = 9) | 40.2 (29.7 - 51.5) | 31.4 (25.3 - 41.3) £. †| 72.3 (53.6 - 82.4) £ | 69.3 (36.3 - 89.3) †| £ p < 0.05. †p < 0.05 |
MFI CXCR4 in CXCR4+ cells | Â | Â | |||
Controls without statins (n = 7) | 34.6 (17.1 - 37.7) | 22.9 (10.6 - 58.4) | 40.1 (16.6 - 58.4) | 29.9 (13.7 - 33.5) | NS |
Lovastatin (n = 10) | 16.3 (12.1 - 26.9) | 9.2 (5.9 - 12.3) | 19.5 (12.8 - 30.3) | 13.4 (9.6 - 64.9) | NS |
Atorvastatin (n = 9) | 10.6 (10.1 - 14.5) | 8.6 (7.6 - 10.3) £. †| 25.0 (13.5 - 28.2) £ | 22.4 (9.7 - 57.9) †| £ p < 0.05. †p < 0.05 |
% CCR5+ | Â | Â | |||
Controls without statins (n = 7) | 56.8 (32.2 - 64.5) | 52.9 (15.7 - 70.3) | 60.9 (32.1 - 72.3) | 79.6 (27.8 - 80.0) | NS |
Lovastatin (n = 10) | 27.3 (21.6 - 41.5) | 22.7 (7.8 - 26.9) | 49.2 (24.0 - 61.8) | 50.5 (18.9 - 73.7) | NS |
Atorvastatin (n = 9) | 23.6 (17.0 - 55.7) | 14.9 (8.5 - 21.3) †| 55.7 (25.8 - 57.2) | 76.1 (27.3 - 78.3) †| †p < 0.05 |
MFI CCR5 in CCR5+ cells | Â | Â | |||
Controls without statins (n = 7) | 15.9 (9.0 - 19.4) | 16.4 (6.0 - 25.2) | 16.1 (10.2 - 29.0) | 18.3 (8.0 - 20.7) | NS |
Lovastatin (n = 10) | 8.6 (7.0 - 13.3) | 7.1 (4.7 - 8.3) | 12.7 (7.5 - 18.5) | 11.8 (6.4 - 27.2) | NS |
Atorvastatin (n = 9) | 7.1 (6.3 - 19.8) | 6.2 (4.7 - 7.5) †| 15.3 (8.0 - 16.1) | 26.0 (8.0 - 29.5) †| †p < 0.05 |